New eye injection PRO-169 enters safety trial for Diabetes-Related vision loss
Disease control
Not yet recruiting
This Phase 1 trial will test the safety of PRO-169, a form of bevacizumab injected into the eye, in 60 adults with diabetic macular edema. The study checks for immune reactions and side effects. It is not yet recruiting and focuses on safety, not whether it improves vision.
Phase: PHASE1 • Sponsor: Laboratorios Sophia S.A de C.V. • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC